Effect of rD-mPGPtide on Donor/Host Chimerism in BM Engraftment Across MHC Barriers
| Strain Combination . | Genetic Difference . | Treatment . | Phenotype, Day 30 (% donor/host) . | Phenotype, Day 60 (% donor/host) . |
|---|---|---|---|---|
| B10.BR → B6 (750 cGy) | Full MHC | PBS | 19/65 | |
| rD-mPGPtide | 53/38 | ND | ||
| Anti-CD4 MoAb | 53/37 | |||
| (B6D2)F1 → (B6CB)F1 (800 cGy) | Haplo-MHC | PBS | 8/87 | 17/76 |
| rD-mPGPtide | 71/21 | 84/13 | ||
| Anti-CD4 MoAb | 75/19 | 86/12 | ||
| bm12 → B6-Ly5.2 (750 cGy) | MHC class II | PBS | 9/73 | 7/85 |
| rD-mPGPtide | 66/26 | 71/20 | ||
| Anti-CD4 MoAb | 62/27 | 69/21 |
| Strain Combination . | Genetic Difference . | Treatment . | Phenotype, Day 30 (% donor/host) . | Phenotype, Day 60 (% donor/host) . |
|---|---|---|---|---|
| B10.BR → B6 (750 cGy) | Full MHC | PBS | 19/65 | |
| rD-mPGPtide | 53/38 | ND | ||
| Anti-CD4 MoAb | 53/37 | |||
| (B6D2)F1 → (B6CB)F1 (800 cGy) | Haplo-MHC | PBS | 8/87 | 17/76 |
| rD-mPGPtide | 71/21 | 84/13 | ||
| Anti-CD4 MoAb | 75/19 | 86/12 | ||
| bm12 → B6-Ly5.2 (750 cGy) | MHC class II | PBS | 9/73 | 7/85 |
| rD-mPGPtide | 66/26 | 71/20 | ||
| Anti-CD4 MoAb | 62/27 | 69/21 |
Data from one experiment representative of three separate experiments are presented as the percentage of positive splenocytes as analyzed by flow cytometry. Chimerism was determined using the following MoAb pairs: FITC-anti-H2Kk (B10.BR) and PE-anti-H2Kb (B6); PE-anti-H2Kb (bm12 and B6-Ly5.2) and FITC-anti-CD45.1 (anti-Ly5.1; B6-Ly5.2); and FITC-anti-H2Kk [(B6CB)F1] and PE-anti-H2Kd [(B6D2)F1]. The mean of samples from five mice per group is presented for each individual treatment. The values in all rD-mPGPtide and anti-CD4 MoAb treatment groups were significantly different from those in the PBS control group, P ≤ .001.
Abbreviation: ND, not done.